In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis | Zendy

Martin Walsh | Zendy; Elizabeth W. Kappus | Zendy; Thomas C. Quinn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis

Author(s) -

Martin Walsh,

Elizabeth W. Kappus,

Thomas C. Quinn

Publication year - 1987

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.31.5.811

Subject(s) - tetracycline , chlamydia trachomatis , clindamycin , erythromycin , antimicrobial , microbiology and biotechnology , in vitro , microgram , antibiotics , chlamydia , regimen , medicine , pharmacology , chemistry , biology , virology , immunology , biochemistry

The antimicrobial activity of CP-62,993 against four Chlamydia trachomatis isolates was compared with those of erythromycin, clindamycin, and tetracycline. The MIC of CP-62,993 was 0.26 to 1.02 micrograms/ml for 100% inclusion inhibition and 0.031 to 0.063 microgram/ml for 50% inclusion inhibition. With pharmacokinetic and antimicrobial studies demonstrating prolonged half-life and in vitro effectiveness, CP-62,993 may make possible a single, short-course treatment regimen for C. trachomatis infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research